Dispersion ablation + PVI for Atrial Fibrillation

Hôpital Privé Jacques Cartier, Massy, France
Atrial FibrillationDispersion ablation + PVI - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests a new, tailored way of performing ablation for atrial fibrillation against the standard method.

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 12 months

12 months
Freedom from documented AF after one ablation procedure
Freedom from documented AF after one or more ablation procedure(s)
Freedom from documented AF/AT after one ablation procedure
Freedom from documented AF/AT after one or more ablation procedure(s)
Freedom from documented AF/AT after one or two ablation procedures
Incidence of complications (safety composite endpoint)

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Anatomical
1 of 2
Tailored
1 of 2

Active Control

Experimental Treatment

377 Total Participants · 2 Treatment Groups

Primary Treatment: Dispersion ablation + PVI · No Placebo Group · N/A

TailoredExperimental Group · 2 Interventions: Dispersion ablation + PVI, VX1 · Intervention Types: Procedure, Device
Anatomical
Procedure
ActiveComparator Group · 1 Intervention: PVI · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months

Who is running the clinical trial?

Volta MedicalLead Sponsor
2 Previous Clinical Trials
132 Total Patients Enrolled
2 Trials studying Atrial Fibrillation
132 Patients Enrolled for Atrial Fibrillation
CovanceIndustry Sponsor
119 Previous Clinical Trials
12,609 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
28 Patients Enrolled for Atrial Fibrillation
CardiaBaseOTHER
3 Previous Clinical Trials
1,141 Total Patients Enrolled
Isabel Deisenhofer, MDStudy ChairDeutsches Herzzentrum Muenchen
7 Previous Clinical Trials
1,176 Total Patients Enrolled
6 Trials studying Atrial Fibrillation
876 Patients Enrolled for Atrial Fibrillation

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are over 18 years old and have not had an AF ablation before.
You have a type of irregular heartbeat called symptomatic AF that hasn't been controlled with at least one medication for heart rhythm disorders.
References

Frequently Asked Questions

What is the scope of individuals participating in this investigation?

"To move forward with this research project, 374 suitable volunteers are required. Washington University in Saint Louis, Missouri and Kansas City Heart Rhythm Institute in Overland Park, Kansas are two of the many sites where participants may enroll." - Anonymous Online Contributor

Unverified Answer

Are there any available positions in this trial that participants can fill?

"Confirmed. The information available on clinicaltrials.gov affirms that this medical experiment is still seeking participants, as it was first posted on February 12th 2021 and updated lastly on May 12th 2022. 374 individuals will be recruited from 9 distinct sites for the study's duration." - Anonymous Online Contributor

Unverified Answer

How many centers are currently managing this experiment?

"Nine locations have opened recruitment for this trial, such as Washington University in Saint Louis, Kansas City Heart Rhythm Institute in Overland Park, and Grandview Medical Center in Birmingham. Additional sites are also available." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.